Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. (Q42730361)

5 November 2017

title

Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. (English)

1 reference

lung small cell carcinoma

5 November 2017

main subject

1 reference

1 reference

5 November 2017

1 reference

5 November 2017

Olga V Surova

1 reference

5 November 2017

Alena Vaculova

series ordinal

1 reference

5 November 2017

language of work or name

English

0 references

publication date

18 July 2011

1 reference

5 November 2017

1 reference

5 November 2017

1 reference

5 November 2017

1 reference

5 November 2017

page(s)

1450-1458

1 reference

Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Differential inactivation of caspase-8 in lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

APO2L/TRAIL expression in human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

HDAC2 deficiency and histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGR135

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGR135

1 reference

5 November 2017

1 reference